Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2019

01-04-2019 | Obesity | Original Contributions

Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial

Authors: Selwyn van Rijn, Yvonne G. M. Roebroek, Charlotte de Jonge, Jan Willem M. Greve, Nicole D. Bouvy

Published in: Obesity Surgery | Issue 4/2019

Login to get access

Abstract

Objective

To evaluate the long-term effect of the duodenal-jejunal bypass liner (DJBL) on weight loss and glycemic control.

Background

Data on the long-term effect of DJBL treatment is still missing.

Methods

From 2010 to 2012, 29 patients were treated with the DJBL at center A and center B, as part of a multicenter randomized controlled trial. Prior to implantation and after removal of the DJBL, all patients underwent standardized physical examination and blood sampling. Four years after removal of the DJBL, included patients underwent standardized physical examination and blood sampling as previously performed during the initial study.

Results

Out of the 29 patients, 15 patients were eligible for follow-up with a median duration of 42 months. Five patients had successfully received additional bariatric surgery. Four years after explantation of the DJBL, median weight in these 15 patients was 102.0 kg (IQR 94.0–124.6), which was not statistically significantly different from the 106.1 kg at baseline (IQR 99.0–128.4). Median BMI changed from 33.1 kg/m2 (IQR 32.3–38.5) at baseline to 33.7 kg/m2 (IQR 31.2–36.9) after follow-up. Patients had a TWL of 2.2% (IQR − 1.3–5.6) compared to baseline weight. None of the parameters were significantly different after follow-up compared to baseline.

Conclusions

The effect of weight reduction of initial DJBL treatment seems to be diminished after 4 years of follow-up. However, larger prospective studies with long-term follow-up need to be conducted in the future.
Literature
1.
Health and Social Care Information Centre LS. Statistics on Obesity. England: Physical Activity and Diet; 2013. NHS, 2013 9 may 2013. Report No.: 2
2.
3.
Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. Vital Health Stat 10. Data from the National Health Survey. 2012;(252):1–207.
4.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840–6.CrossRefPubMed
5.
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–80.CrossRefPubMed
6.
7.
Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity. 2013;21(Suppl 1):S1–27.CrossRefPubMed
8.
Maiz C, Alvarado J, Quezada N, et al. Bariatric surgery in 1119 patients with preoperative body mass index < 35 (kg/m(2)): results at 1 year. Surg Obes Relat Dis. 2015;11(5):1127–32.CrossRefPubMed
9.
O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144(9):625–33.CrossRefPubMed
10.
Sultan S, Parikh M, Youn H, et al. Early U.S. outcomes after laparoscopic adjustable gastric banding in patients with a body mass index less than 35 kg/m2. Surg Endosc. 2009;23(7):1569–73.CrossRefPubMed
11.
Mathus-Vliegen EM. Endoscopic treatment: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28(4):685–702.CrossRefPubMed
12.
van Rijn S, Roebroek YG, Masclee AA, et al. Structural endoscopic techniques to treat obesity: a review. Surg Technol Int. 2015;26:84–91.PubMed
13.
Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefPubMed
14.
Betzel B, Homan J, Aarts EO, Janssen IM, de Boer H, Wahab PJ, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2016.
15.
Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012 Jun;255(6):1080–5.CrossRefPubMed
16.
de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.CrossRefPubMed
17.
Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefPubMed
18.
Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.CrossRefPubMed
19.
Diamantis T, Apostolou KG, Alexandrou A, et al. Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(1):177–83.CrossRefPubMed
20.
Edholm D, Svensson F, Naslund I, et al. Long-term results 11 years after primary gastric bypass in 384 patients. Surg Obes Relat Dis. 2013;9(5):708–13.CrossRefPubMed
21.
Mehaffey JH, LaPar DJ, Clement KC, et al. 10-year outcomes after Roux-en-Y gastric bypass. Ann Surg. 2016;264(1):121–6.CrossRefPubMed
22.
Betzel B, Koehestanie P, Aarts EO, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc. 2015;82(5):845–52.CrossRefPubMed
23.
Koehestanie P, Betzel B, Aarts EO, et al. Is reimplantation of the duodenal-jejunal bypass liner feasible? Surg Obes Relat Dis. 2015;11(5):1099–104.CrossRefPubMed
24.
Langeveld M, DeVries JH. The long-term effect of energy restricted diets for treating obesity. Obesity. 2015;23(8):1529–38.CrossRefPubMed
Metadata
Title
Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial
Authors
Selwyn van Rijn
Yvonne G. M. Roebroek
Charlotte de Jonge
Jan Willem M. Greve
Nicole D. Bouvy
Publication date
01-04-2019
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2019
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-03659-6

Other articles of this Issue 4/2019

Obesity Surgery 4/2019 Go to the issue

Video Submission

Modifying an Intragastric Balloon for the Treatment of Obesity: a Unique Approach

Original Contributions

Pre-surgical Weight Loss Predicts Post-surgical Weight Loss Trajectories in Adolescents Enrolled in a Bariatric Program

Original Contributions

Unexpected Intraoperative Findings, Situations, and Complications in Bariatric Surgery

Letter to Editor/LED Reply

Reply to “Laparoscopic Conversion of One Anastomosis Gastric Bypass to Roux-en-Y Gastric Bypass”

Original Contributions

Short- and Long-Term Effects of Bariatric Surgery on Vascular Phenotype

Original Contributions

Risk Factors for Relapse of Hyperglycemia after Laparoscopic Roux-en-Y Gastric Bypass in T2DM Obese Patients: a 5-Year Follow-Up of 24 Cases